APSR2026-157

 
Late-Breaking
Submitted
Poster Presentation
 
AP02-029
P37
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1211097-46904-APSR-157_440263.pdf
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
9

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Parami Munasinghe * National Hospital for Respiratory Diseases Respiratory medicine Welisara Sri Lanka
Manjula Nanayakkara - National STD/AIDS Control Programme, Ministry of Health Venereology Colombo Sri Lanka
Disni De Zoysa - National Hospital for Respiratory Diseases Respiratory medicine Welisara Sri Lanka
Wasanthi Hemamala - National STD/AIDS Control Programme, Ministry of Health Venereology Colombo Sri Lanka
Geethani Samaraweera - STD Clinic, Colombo North Teaching Hospital Venereology Ragama Sri Lanka
Sumudu Palihawadana - National Hospital for Respiratory Diseases Radiology Welisara Sri Lanka
Eshanth Perera - National Hospital for Respiratory Diseases Respiratory medicine Welisara Sri Lanka
Damith Rodrigo - National Hospital for Respiratory Diseases Respiratory medicine Welisara Sri Lanka
Bodhika Samarasekara - National Hospital for Respiratory Diseases Respiratory medicine Welisara Sri Lanka
 
 
 
 
 
 
Presenting Author Details
Parami
Munasinghe
paramivm@gmail.com
+94765508719
31-40
Sri Lanka
Case Report
Refractory severe Pneumocystis jirovecii Pneumonia in immunocompromised hosts: diagnostic and therapeutic challenges from a case series
Maximum 25 words
Abstract Content
 
 
 
 
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection affecting immunocompromised, most commonly those with advanced Human Immunodeficiency Virus (HIV) infection. While PJP incidence has declined with widespread antiretroviral therapy (ART), cases among non-HIV immunocompromised individuals are rising, often with higher mortality. We report three severe PJP cases highlighting atypical presentations, diagnostic and therapeutic challenges in resource-limited settings.
The three patients highlighted here are with severe PJP and diverse immunosuppressive states. The first patient was a young, previously undiagnosed individual presenting with HIV and PJP that failed to respond to both conventional cotrimoxazole therapy and second-line treatment with primaquine and clindamycin. The second patient, also a young previously undiagnosed HIV positive individual, presented with PJP complicated by bilateral pneumothoraces and concurrent Cytomegalovirus (CMV) pneumonitis, with no clinical improvement despite standard or second-line PJP therapy and intravenous ganciclovir. The third patient was an elderly man with hypertension and a history of prolonged excessive alcohol consumption. He presented with PJP alongside pulmonary tuberculosis and similarly exhibited a poor response to treatment indicating the significant burden of PJP in immunocompromised patients. Diagnosis of PJP was based on clinical, radiological, biochemical, and microbiological assessments, with limited access to Nucleic Acid Amplification Testing hindering confirmatory testing. Complications such as pneumothorax, CMV co-infection, drug toxicities, and delayed or modified antiretroviral therapy contributed to poor outcomes and a high fatality rate.
This case series underscores the complexities of managing life threatening PJP in immunocompromised with sinister complications. Timing of ART requires vigilance due to profound risk of immune reconstitution inflammatory syndrome and potential drug adversities. Since PJP isn't uncommon in non-HIV immunocompromised individuals, confirmatory testing becomes essential as initial HIV screening may yield false positives. Clinicians should maintain a high index of suspicion for non-resolving pneumonia, offer early HIV screening and adapt a multidisciplinary approach for management.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Pneumocystis jirovecii Pneumonia, Human Immunodeficiency Virus infection, Immunocompromised host
maximum 3 keywords and no abbreviations, separated by commas
The authors declare that there are no conflicts of interest related to this work. No external funding was received for this study. The authors have no financial relationships or affiliations that could be perceived as influencing the content of this abstract. Informed consent was obtained from the patient's legally authorized representatives for publication of this case series. Institutional ethical standards were adhered to in the preparation of this report.
300